PLX · Protalix BioTherapeutics Inc. (DE) Common Stock
View on chartInsiders & Stakes
| Eyal Rubin Sr. VP and CFO | ▲ Buy | Grant | 669,010 Shares held | 9/23/2024 | View profile |
| Yaron Naos Sr. VP, Operations | ▲ Buy | Grant | 225,817 Shares held | 9/3/2025 | View profile |
| Dror Bashan President and CEO | ▲ Buy | Open Market | 188,516 Shares held | 12/19/2025 | View profile |
| Yael Hayon VP, Research & Development | ▲ Buy | Grant | 35,115 Shares held | 8/15/2023 | View profile |
| Eliot Forster | ▲ Buy | Grant | 7,500 Shares held | 9/3/2025 | View profile |
| Gwen A. Melincoff Director | ▲ Buy | Grant | 7,500 Shares held | 9/3/2025 | View profile |
| Pol F. Boudes | ▲ Buy | Grant | 7,500 Shares held | 9/3/2025 | View profile |
| Christian Elze | ▲ Buy | Grant | 7,500 Shares held | 9/3/2025 | View profile |
| Aharon Schwartz Director | ▲ Buy | Grant | 7,500 Shares held | 9/3/2025 | View profile |
| Zvi Shmuel Ben | ▲ Buy | Grant | 7,500 Shares held | 9/3/2025 | View profile |
| Amos Bar-Shalev | ▼ Sell | Open Market | 0 Shares held | 11/18/2025 | View profile |
Transaction History
| Dror Bashan | ▲ Buy | Open Market | 56,000 | $101K | 12/19/2025 |
| Amos Bar-Shalev | ▼ Sell | Open Market | 168 | $314 | 11/18/2025 |
| Christian Elze | ▲ Buy | Grant | 7,500 | — | 9/3/2025 |
| Aharon Schwartz | ▲ Buy | Grant | 7,500 | — | 9/3/2025 |
| Zvi Shmuel Ben | ▲ Buy | Grant | 7,500 | — | 9/3/2025 |
| Amos Bar-Shalev | ▲ Buy | Grant | 7,500 | — | 9/3/2025 |
| Yaron Naos | ▲ Buy | Grant | 25,000 | — | 9/3/2025 |
| Eliot Forster | ▲ Buy | Grant | 7,500 | — | 9/3/2025 |
| Gwen A. Melincoff | ▲ Buy | Grant | 7,500 | — | 9/3/2025 |
| Pol F. Boudes | ▲ Buy | Grant | 7,500 | — | 9/3/2025 |
| Dror Bashan | ▲ Buy | Grant | 195,000 | — | 9/3/2025 |
| Aharon Schwartz | ▲ Buy | Open Market | 129,000 | $206K | 6/10/2025 |
| Eyal Rubin | ▲ Buy | Grant | 99,010 | — | 9/23/2024 |
| Dror Bashan | ▲ Buy | Grant | 263,960 | — | 4/1/2024 |
| Dror Bashan | ▲ Buy | Open Market | 48,387 | $68K | 10/19/2023 |
| Dror Bashan | ▲ Buy | Open Market | 16,129 | $23K | 10/19/2023 |
| Eyal Rubin | ▲ Buy | Grant | 201,903 | — | 8/15/2023 |
| Yaron Naos | ▲ Buy | Grant | 187,344 | — | 8/15/2023 |
| Dror Bashan | ▲ Buy | Grant | 800,000 | — | 8/15/2023 |
| Yael Hayon | ▲ Buy | Grant | 35,115 | — | 8/15/2023 |
| Aharon Schwartz | ▲ Buy | Open Market | 110,000 | $156K | 1/3/2023 |
| Dror Bashan | ▲ Buy | Open Market | 68,000 | $102K | 4/11/2022 |
| Eyal Rubin | ▲ Buy | Grant | 121,951 | — | 2/25/2022 |
| Dror Bashan | ▲ Buy | Grant | 637,531 | — | 2/25/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
PLX: No direct news; broader market analyst moves noted
Recent news coverage focuses on analyst actions for other companies like Netflix and SanDisk, with no specific updates reported for Protalix BioTherapeutics. The stock currently trades within its 52-week range of $1.60 to $3.19, holding above the identified support level of $2.31. While technical signals show some divergence, the lack of company-specific headlines keeps the immediate news impact low.
PLX: No direct news; broader market analyst moves noted. Recent news coverage focuses on analyst actions for other companies like Netflix and SanDisk, with no specific updates reported for Protalix BioTherapeutics. The stock currently trades within its 52-week range of $1.60 to $3.19, holding above the identified support level of $2.31. While technical signals show some divergence, the lack of company-specific headlines keeps the immediate news impact low.